Korea
  • Europe
  • Britain
  • Germany
  • France
  • Italy
  • Spain
  • Poland
  • Netherlands
  • Russia
  • Iran
  • Japan
  • Canada
  • Australia
  • Africa
  • AI
  • Korea
  • Bank of Korea
  • Coupang
  • Doosan
  • Hanwha
  • Hanwha Aerospace
  • Hanwha Ocean
  • HD Hyundai Heavy
  • Hyundai
  • Hyundai Motor
  • Kakao
  • Korea
  • Korea Exchange
  • LG
  • LG Electronics
  • LG Energy Solution
  • Naver
  • North Korea
  • POSCO
  • Pyongyang
  • Samsung
  • Samsung Biologics
  • Samsung Electronics
  • Seoul
  • SK
  • SK Hynix
  • SK Square
  • South Korea
Korea
  • Europe
  • Britain
  • Germany
  • France
  • Italy
  • Spain
  • Poland
  • Netherlands
  • Russia
  • Iran
  • Japan
  • Canada
  • Australia
  • Africa
  • AI
  • Korea

Browsing Tag

PolyPeptide Group

20 posts
SSamsung Biologics
Samsung Biologics Labor and Management End 100-Day Standoff, Accept Post-Adjustment to Seek Resolution Within the Year — BigGo Finance
Read More

Samsung Biologics Labor and Management End 100-Day Standoff, Accept Post-Adjustment to Seek Resolution Within the Year — BigGo Finance

  • August 20, 2026
Samsung Biologics (207940.KS) labor and management have agreed to end their wage and collective bargaining agreement standoff that…
SSamsung Biologics
China's WuXi AppTec Surpasses $4.3 Billion in First-Half Revenue, Overtaking Lonza to Target Global CDMO Crown — BigGo Finance
Read More

China’s WuXi AppTec Surpasses $4.3 Billion in First-Half Revenue, Overtaking Lonza to Target Global CDMO Crown — BigGo Finance

  • August 9, 2026
China’s contract development and manufacturing organization (CDMO) WuXi AppTec has shaken up the global CDMO market by surpassing…
SSamsung Biologics
Samsung Biologics First-Half Operating Profit Tops ₩1 Trillion; Annual Revenue of ₩5 Trillion Within Reach — BigGo Finance
Read More

Samsung Biologics First-Half Operating Profit Tops ₩1 Trillion; Annual Revenue of ₩5 Trillion Within Reach — BigGo Finance

  • July 24, 2026
Samsung Biologics (207940) has surpassed ₩1 trillion (approximately $678.2 million) in half-year operating profit for the first time…
SSamsung Biologics
Samsung Biologics Quarterly Revenue Tops ₩1.3 Trillion for First Time; Operating Profit Surges 23% — BigGo Finance
Read More

Samsung Biologics Quarterly Revenue Tops ₩1.3 Trillion for First Time; Operating Profit Surges 23% — BigGo Finance

  • July 24, 2026
Samsung Biologics shattered its quarterly revenue record, surpassing ₩1.3 trillion (approximately $885.9 million) for the first time since…
SSamsung Biologics
Meritz Securities Cuts Samsung Biologics Target to approximately $1,363, Says Rebound Difficult Without Major Orders — BigGo Finance
Read More

Meritz Securities Cuts Samsung Biologics Target to approximately $1,363, Says Rebound Difficult Without Major Orders — BigGo Finance

  • July 24, 2026
Meritz Securities has lowered its target price for Samsung Biologics (207940.KS) from ₩2.3 million to ₩2 million (approximately…
SSamsung Biologics
Samsung Biologics, Celltrion Post Surprise Q2 Earnings; Both Eye ₩5 Trillion Annual Revenue Milestone — BigGo Finance
Read More

Samsung Biologics, Celltrion Post Surprise Q2 Earnings; Both Eye ₩5 Trillion Annual Revenue Milestone — BigGo Finance

  • July 23, 2026
South Korea’s two biopharmaceutical frontrunners, Samsung Biologics and Celltrion, posted second-quarter earnings that exceeded market expectations, setting the…
SSamsung Biologics
Samsung Biologics Q2 Operating Profit Hits ₩586.4 Billion (approximately $397.2 Million), Up 23% YoY — BigGo Finance
Read More

Samsung Biologics Q2 Operating Profit Hits ₩586.4 Billion (approximately $397.2 Million), Up 23% YoY — BigGo Finance

  • July 23, 2026
Samsung Biologics (207940) posted second-quarter consolidated revenue of ₩1.32 trillion (approximately $894.7 million) and operating profit of ₩586.4…
SSamsung Biologics
Samsung Biologics Acquires Swiss CDMO for approximately $1.8 Billion, Making a Major Push into the Obesity Drug Market — BigGo Finance
Read More

Samsung Biologics Acquires Swiss CDMO for approximately $1.8 Billion, Making a Major Push into the Obesity Drug Market — BigGo Finance

  • July 22, 2026
Samsung Biologics (207940) is investing approximately 2.7 trillion won (approximately $1.8 billion) to acquire PolyPeptide Group, a global…
SSamsung Biologics
Samsung Biologics Acquires Swiss PolyPeptide Group for approximately $1.8 Billion, Targeting Obesity Drug Market — BigGo Finance
Read More

Samsung Biologics Acquires Swiss PolyPeptide Group for approximately $1.8 Billion, Targeting Obesity Drug Market — BigGo Finance

  • July 21, 2026
Samsung Biologics is making a blockbuster acquisition of PolyPeptide Group AG, a Swiss peptide contract development and manufacturing…
SSamsung Biologics
Samsung Biologics Bets $1.8 Billion on 'K-Obesity Drug' Play with Swiss PolyPeptide Acquisition — BigGo Finance
Read More

Samsung Biologics Bets $1.8 Billion on ‘K-Obesity Drug’ Play with Swiss PolyPeptide Acquisition — BigGo Finance

  • July 21, 2026
Samsung Biologics has thrown its hat into the rapidly growing global obesity treatment market, committing 2.7 trillion won…
SSamsung Biologics
Samsung Group affiliates' major investments in medical and bio-related companies. Seoul Economic Daily - Seoul Economic Daily Finance News from South Korea
Read More

Why Samsung’s 2.7 Trillion Won Deal Signals Its Galaxy Healthcare Push

  • July 21, 2026
[CAPTIONS] Samsung Electronics Chairman Lee Jae-yong. Yonhap News Samsung Biologics’ move into the largest merger and acquisition in…
SSamsung Biologics
Samsung Group affiliates' major investments in medical and bio-related companies. Seoul Economic Daily - Seoul Economic Daily Finance News from South Korea
Read More

Why Samsung’s 2.7 Trillion Won Deal Signals Its Galaxy Healthcare Push

  • July 21, 2026
[CAPTIONS] Samsung Electronics Chairman Lee Jae-yong. Yonhap News Samsung Biologics’ move into the largest merger and acquisition in…
Korea
www.europesays.com